Immune Response Corp. said it has finished enrolling HIV-infected patients into its Phase II/III clinical trial of avaccine for AIDS. The double-blind, placebo-controlled trial ofthe vaccine, which contains twice-killed virus, is expected toend in September 1992.
The trial at nine U.S. sites is sponsored by a joint venturebetween the Carlsbad, Calif.-based company and Rhone-PoulencRorer Inc. One hundred patients will be monitored for theeffect of the therapeutic vaccine on the level of virus in theirblood. The company does not have immediate plans to marketthe vaccine, which is whole virus irradiated and thenchemically killed, as an AIDS preventative.
However, Immune Response (NASDAQ:IMNR) said it is convincedits vaccine is not infective and is considering testing it in asmall number of non-infected volunteers, perhaps in 1992.
(c) 1997 American Health Consultants. All rights reserved.